R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Diana Al-Sarayfi; Frederik O. Meeuwes; Müjde Durmaz; Djamila E. Issa; Rolf E. Brouwer; Aart Beeker; Anna van Rhenen; Pim G.N.J. Mutsaers; Lara H. Böhmer; Marjolein W.M. van der Poel; Liane te Boome; Tom van Meerten; Martine E.D. Chamuleau; Josée M. Zijlstra; Mirian Brink; Marcel Nijland

doi:10.1038/s41408-022-00723-4

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Diana Al-Sarayfi, Frederik O. Meeuwes, Müjde Durmaz, Djamila E. Issa, Rolf E. Brouwer, Aart Beeker, Anna van Rhenen, Pim G.N.J. Mutsaers, Lara H. Böhmer, Marjolein W.M. van der Poel, Liane te Boome, Tom van Meerten, Martine E.D. Chamuleau, Josée M. Zijlstra, Mirian Brink, Marcel Nijland^*

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Academic › peer-review

13 Downloads (Pure)

Original language	English
Article number	125
Journal	Blood cancer journal
Volume	12
Issue number	9
DOIs	https://doi.org/10.1038/s41408-022-00723-4
Publication status	Published - 2 Sept 2022

Keywords

Anthracyclines/therapeutic use
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Cyclophosphamide/therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse/pathology
Prednisone/therapeutic use
Treatment Outcome
Vincristine/therapeutic use

Access to Document

10.1038/s41408-022-00723-4Licence: CC BY

s41408-022-00723-4Final published version, 594 KBLicence: CC BY

Cite this

Al-Sarayfi, D., Meeuwes, F. O., Durmaz, M., Issa, D. E., Brouwer, R. E., Beeker, A., van Rhenen, A., Mutsaers, P. G. N. J., Böhmer, L. H., van der Poel, M. W. M., te Boome, L., van Meerten, T., Chamuleau, M. E. D., Zijlstra, J. M., Brink, M., & Nijland, M. (2022). R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma. Blood cancer journal, 12(9), Article 125. https://doi.org/10.1038/s41408-022-00723-4

@article{3a75eaf9deb64d4aa0b01b7b184f425b,

title = "R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma",

keywords = "Anthracyclines/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Cyclophosphamide/therapeutic use, Humans, Lymphoma, Large B-Cell, Diffuse/pathology, Prednisone/therapeutic use, Treatment Outcome, Vincristine/therapeutic use",

author = "Diana Al-Sarayfi and Meeuwes, {Frederik O.} and M{\"u}jde Durmaz and Issa, {Djamila E.} and Brouwer, {Rolf E.} and Aart Beeker and {van Rhenen}, Anna and Mutsaers, {Pim G.N.J.} and B{\"o}hmer, {Lara H.} and {van der Poel}, {Marjolein W.M.} and {te Boome}, Liane and {van Meerten}, Tom and Chamuleau, {Martine E.D.} and Zijlstra, {Jos{\'e}e M.} and Mirian Brink and Marcel Nijland",

year = "2022",

month = sep,

day = "2",

doi = "10.1038/s41408-022-00723-4",

language = "English",

volume = "12",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "9",

}

Al-Sarayfi, D, Meeuwes, FO, Durmaz, M, Issa, DE, Brouwer, RE, Beeker, A, van Rhenen, A, Mutsaers, PGNJ, Böhmer, LH, van der Poel, MWM, te Boome, L, van Meerten, T, Chamuleau, MED, Zijlstra, JM, Brink, M & Nijland, M 2022, 'R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma', Blood cancer journal, vol. 12, no. 9, 125. https://doi.org/10.1038/s41408-022-00723-4

TY - JOUR

T1 - R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

AU - Al-Sarayfi, Diana

AU - Meeuwes, Frederik O.

AU - Durmaz, Müjde

AU - Issa, Djamila E.

AU - Brouwer, Rolf E.

AU - Beeker, Aart

AU - van Rhenen, Anna

AU - Mutsaers, Pim G.N.J.

AU - Böhmer, Lara H.

AU - van der Poel, Marjolein W.M.

AU - te Boome, Liane

AU - van Meerten, Tom

AU - Chamuleau, Martine E.D.

AU - Zijlstra, Josée M.

AU - Brink, Mirian

AU - Nijland, Marcel

PY - 2022/9/2

Y1 - 2022/9/2

KW - Anthracyclines/therapeutic use

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Cyclophosphamide/therapeutic use

KW - Humans

KW - Lymphoma, Large B-Cell, Diffuse/pathology

KW - Prednisone/therapeutic use

KW - Treatment Outcome

KW - Vincristine/therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=85137155048&partnerID=8YFLogxK

U2 - 10.1038/s41408-022-00723-4

DO - 10.1038/s41408-022-00723-4

M3 - Letter

C2 - 36055987

SN - 2044-5385

VL - 12

JO - Blood cancer journal

JF - Blood cancer journal

IS - 9

M1 - 125

ER -

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Keywords

Access to Document

Other files and links

Cite this